BamSEC and AlphaSense Join Forces
Learn More

Eloxx Pharmaceuticals Inc. – Material Contracts

OTC: ELOXD    
Share price (6/5/26): $6.20    
Market cap (6/5/26): $47.0 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.60
from S-1/A 16 pages Amended and Restated Pre-Funded Warrant to Purchase Common Stock
12/34/56
EX-10.59
from S-1/A 16 pages Pre-Funded Warrant to Purchase Common Stock
12/34/56
EX-10.58
from S-1/A 22 pages Eloxx Pharmaceuticals, Inc. Amended and Restated 2018 Equity Incentive Plan Adopted by the Board of Directors: April 28, 2026 Approved by the Stockholders: April 28, 2026 Effective Date: April 28, 2026
12/34/56
EX-10.55
from S-1/A 23 pages Registration Rights Agreement
12/34/56
EX-10.16
from S-1/A 11 pages Consulting Agreement
12/34/56
EX-10.58
from S-1 22 pages Eloxx Pharmaceuticals, Inc. Amended and Restated 2018 Equity Incentive Plan Adopted by the Board of Directors: April [●], 2026 Approved by the Stockholders: April [●], 2026 Effective Date: April [●], 2026
12/34/56
EX-10.4
from 10-Q 17 pages Amended and Restated Pre-Funded Warrant to Purchase Common Stock
12/34/56
EX-10.54
from 10-K 17 pages Form of Pre-Funded Warrant to Purchase Common Stock
12/34/56
EX-10.53
from 10-K 22 pages Registration Rights Agreement
12/34/56
EX-10.51
from 10-K 11 pages Third Amendment to Securities Purchase Agreement
12/34/56
EX-10.50
from 10-K 9 pages Second Amendment to Securities Purchase Agreement
12/34/56
EX-10.49
from 10-K 6 pages Amendment to Securities Purchase Agreement
12/34/56
EX-10.48
from 10-K 43 pages Securities Purchase Agreement
12/34/56
EX-10.47
from 10-K 29 pages [***] Certain Information in This Document Has Been Excluded Pursuant to Regulation S-K, Item 601(b)(10). Such Excluded Information Is Not Material and Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed
12/34/56
EX-10.46
from 10-K 18 pages Common Stock Purchase Warrant ELOXX Pharmaceuticals, Inc
12/34/56
EX-10.44
from 10-K 44 pages Securities Purchase Agreement This Securities Purchase Agreement (This “Agreement”) Is Made as of January 9, 2024 (The “Effective Date”) by and Between ELOXX Pharmaceuticals, Inc, a Delaware Corporation (The “Company”), and Sd Mf 4 LLC, a Delaware Limited Liability Company (The “Purchaser”). 1
12/34/56
EX-10.41
from 10-K 115 pages [***] Certain Information in This Document Has Been Excluded Pursuant to Regulation S-K, Item 601(b)(10). Such Excluded Information Is Not Material and Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed. Dated March 11, 2024
12/34/56
EX-10.40
from 10-K 7 pages [***] Certain Information in This Document Has Been Excluded Pursuant to Regulation S-K, Item 601(b)(10). Such Excluded Information Is Not Material and Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed. Amendment No. 1 to Amended and Restated License Agreement
12/34/56
EX-10.39
from 10-K 46 pages [***] Certain Information in This Document Has Been Excluded Pursuant to Regulation S-K, Item 601(b)(10). Such Excluded Information Is Not Material and Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed. Amended and Restated License Agreement
12/34/56
EX-10.38
from 10-K 7 pages [***] Certain Information in This Document Has Been Excluded Pursuant to Regulation S-K, Item 601(b)(10). Such Excluded Information Is Not Material and Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed. Omnibus Agreement
12/34/56